Abstract
We previously studied hypoxic tumor cells from hepatic metastases of colorectal cancer (CRC) and determined several potential prognostic factors, including expression of ephrin-A1 (EFNA1), which was highly induced by hypoxia. Here, we further evaluated the prognostic impact of EFNA1 expression. Samples from a total of 366 CRC patients from 11 institutes were analyzed by either microarray (n=220) or quantitative reverse-transcriptase polymerase chain reaction (n=146). EFNA1 was an independent prognostic factor for CRC (p<0.05). In vitro assays revealed that loss of EFNA1 following siRNA treatment was associated with reduced proliferative activity and decreased invasion and migration of CRC cell lines. EFNA1 expression is a useful marker for predicting high risk of relapse and cancer-related death in patients who have undergone curative resection for CRC.
| Original language | English |
|---|---|
| Pages (from-to) | 549-555 |
| Number of pages | 7 |
| Journal | International journal of oncology |
| Volume | 42 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 1 2013 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
Ephrin-A1 mRNA is associated with poor prognosis of colorectal cancer. / Yamamoto, Hirofumi; Tei, Mitsuyoshi; Uemura, Mamoru; Takemasa, Ichiro; Uemura, Yoshio; Murata, Kohei; Fukunaga, Mutsumi; Ohue, Masayuki; Ohnishi, Tadashi; Ikeda, Kimimasa; Kato, Takeshi; Okamura, Shu; Ikenaga, Masakazu; Haraguchi, Naotsugu; Nishimura, Junichi; Mizushima, Tsunekazu; Mimori, Koshi; Doki, Yuichiro; Mori, Masaki.
In: International journal of oncology, Vol. 42, No. 2, 01.02.2013, p. 549-555.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ephrin-A1 mRNA is associated with poor prognosis of colorectal cancer
AU - Yamamoto, Hirofumi
AU - Tei, Mitsuyoshi
AU - Uemura, Mamoru
AU - Takemasa, Ichiro
AU - Uemura, Yoshio
AU - Murata, Kohei
AU - Fukunaga, Mutsumi
AU - Ohue, Masayuki
AU - Ohnishi, Tadashi
AU - Ikeda, Kimimasa
AU - Kato, Takeshi
AU - Okamura, Shu
AU - Ikenaga, Masakazu
AU - Haraguchi, Naotsugu
AU - Nishimura, Junichi
AU - Mizushima, Tsunekazu
AU - Mimori, Koshi
AU - Doki, Yuichiro
AU - Mori, Masaki
PY - 2013/2/1
Y1 - 2013/2/1
N2 - We previously studied hypoxic tumor cells from hepatic metastases of colorectal cancer (CRC) and determined several potential prognostic factors, including expression of ephrin-A1 (EFNA1), which was highly induced by hypoxia. Here, we further evaluated the prognostic impact of EFNA1 expression. Samples from a total of 366 CRC patients from 11 institutes were analyzed by either microarray (n=220) or quantitative reverse-transcriptase polymerase chain reaction (n=146). EFNA1 was an independent prognostic factor for CRC (p<0.05). In vitro assays revealed that loss of EFNA1 following siRNA treatment was associated with reduced proliferative activity and decreased invasion and migration of CRC cell lines. EFNA1 expression is a useful marker for predicting high risk of relapse and cancer-related death in patients who have undergone curative resection for CRC.
AB - We previously studied hypoxic tumor cells from hepatic metastases of colorectal cancer (CRC) and determined several potential prognostic factors, including expression of ephrin-A1 (EFNA1), which was highly induced by hypoxia. Here, we further evaluated the prognostic impact of EFNA1 expression. Samples from a total of 366 CRC patients from 11 institutes were analyzed by either microarray (n=220) or quantitative reverse-transcriptase polymerase chain reaction (n=146). EFNA1 was an independent prognostic factor for CRC (p<0.05). In vitro assays revealed that loss of EFNA1 following siRNA treatment was associated with reduced proliferative activity and decreased invasion and migration of CRC cell lines. EFNA1 expression is a useful marker for predicting high risk of relapse and cancer-related death in patients who have undergone curative resection for CRC.
UR - http://www.scopus.com/inward/record.url?scp=84873658823&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873658823&partnerID=8YFLogxK
U2 - 10.3892/ijo.2012.1750
DO - 10.3892/ijo.2012.1750
M3 - Article
C2 - 23258614
AN - SCOPUS:84873658823
VL - 42
SP - 549
EP - 555
JO - International Journal of Oncology
JF - International Journal of Oncology
SN - 1019-6439
IS - 2
ER -